Brief: MAIA Biotechnology Announces Positive Survival Updates In Phase 2 Study Of Thio In Non-Small Cell Lung Cancer
10/09/2024 12:17
Sept 10 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY ANNOUNCES POSITIVE SURVIVAL UPDATES IN
PHASE
2 STUDY OF THIO IN NON-SMALL CELL LUNG CANCER
* MAIA BIOTECHNOLOGY INC - 16 PATIENTS SURPASSED 12-MONTH
SURVIVAL
FOLLOW-UP
* MAIA BIOTECHNOLOGY INC - THIO FOLLOWED BY LIBTAYO
GENERALLY
WELL-TOLERATED
* MAIA BIOTECHNOLOGY INC - EXPECTS TO RELEASE FULL EFFICACY
RESULTS OF THIO-101 THIS YEAR
Source text for Eikon: ID:nBwc1FB52a
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale